Launch of US Kidney Care National Plan

Verici Dx PLC

22 October 2026

 

Verici Dx plc

(“Verici Dx” or the “Company”)

Launch of US Kidney Care National Plan

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, welcomes the launch of the Kidney Care National Plan by the US Department of Health and Human Services (“HHS”), a coordinated strategy focused on revitalizing American kidney care.

The 2026 Kidney Care National Plan centres on three priorities:

• Prevent Kidney Failure: Detect kidney disease earlier, intervene sooner, and advance treatments and technologies that can slow or stop disease progression.
• Improve Dialysis Care and Expand Patient Choice: Promote competition, reduce barriers to entry for new providers and treatments, expand access to home-based care, and support innovations that improve outcomes and quality of life.
• Reform Transplantation: Strengthen safety, transparency, and accountability across the transplant system while expanding access to living and deceased-donor transplantation.

Commenting, Sara Barrington, CEO of Verici Dx, said:

“Expanding access to transplantation is essential, but so is making the most of every transplant. For transplant teams, that means having better information to assess rejection risk and inform decisions about patient management.”

“As we work toward a future where more patients can benefit from kidney transplantation, we also need to focus on the tools that can help clinicians make informed decisions throughout the transplant journey. At Verici Dx, we’re addressing this need. Our Tutivia® test classifies kidney transplant recipients as having a low or high risk of acute rejection, giving clinicians additional data-driven information as they manage patients after transplant.”

A Press Release from the US Department of Health and Human Services is available here:

HHS Launches Landmark National Plan to Transform Kidney Care in America | HHS.gov

A PDF of the full Kidney Care National Plan is available here:

https://aspe.hhs.gov/sites/default/files/documents/854a21edb42e2cda8e9009d4a4d466a1/Kidney_Care_National_Plan.pdf

Verici Dx plc	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser, Joint Broker & Joint Bookrunner)		Tel: [phone]
Russell Cook / Anastassiya Eley / Harry Littlewood
Oberon Capital (Joint Broker & Joint Bookrunner)	Tel: [phone]
Mike Seabrook / Heena Karani
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Alice Woodings / Rachel Broad	Mob: [phone]

About Verici Dx plc www.vericidx.com

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines transcriptomic analysis with proprietary tests with underlying technology based upon artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that the Company believes answer the clinical questions that matter most with clarity and precision. All commercially available tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com and follow us on LinkedIn.

in Cardiff for the UK, and in Franklin, Tennessee for the U.S.

 

END